September 23, 2017 |
New PAD Clinical Trial - Texas Heart Institute
October 15, 2013  | 

Houston, TX – Doctors and researchers at the Texas Heart Institute (THI) are recruiting patients who suffer from peripheral artery disease (PAD) for a new clinical trial to assess the benefits and risks in the use of adult stem cells from patients’ own bone marrow to treat leg pain commonly associated with the disease.

PAD affects between 8 million and 10 million Americans. The primary leg symptom is called “intermittent claudication”, which can manifest as aching, cramps, numbness or feeling of fatigue in the leg muscles. These symptoms occur in approximately 1 million to 3 million sufferers of the disease.   

Many with PAD may not be able to enjoy a relief of these leg symptoms with any of the currently available therapies, which range from exercise to medications to endovascular and open surgical options. Many current treatments are associated with risk, may not provide longstanding symptom relief, and/or are not cost-effective.

“Cell therapy has been studied in patients with heart disease and severe PAD,” said Dr. Emerson Perin, director of THI’s Stem Cell Center, “But, it has not been adequately evaluated in individuals with intermittent claudication.  We are hoping to change that.”

The PACE trial (Patients with Intermittent Claudication Injected with ALDH Bright Cells), is being conducted under the auspices  of the  Cardiovascular Cell Therapy Network (CCTRN), a network of cell research centers, including THI, sponsored by the National Heart Lung and Blood Institute (NHLBI).   Continue>

Page | 1 2
Suggested Articles